CLL-IPI (International Prognostic Index for CLL)
Integrates genetic, biological, and clinical factors to predict outcome in CLL. Score 0–10.
Score interpretation
Low risk. 5-year OS ~93%.
→ Watch and wait. Annual review.
Intermediate risk. 5-year OS ~79%.
→ Monitoring every 3–6 months. Treat when active disease criteria met.
High risk. 5-year OS ~64%.
→ Consider early treatment in clinical trial. BTK inhibitors or venetoclax-based regimens preferred.
Very high risk. 5-year OS ~23%. TP53 dysfunction likely.
→ BTK inhibitor (ibrutinib/acalabrutinib) or venetoclax-obinutuzumab. Allo-SCT if eligible. Clinical trial strongly preferred.
Interpretation bands for the CLL-IPI. Apply clinical judgement and local guidance.
References
- International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for CRC Liver Metastases · Cancer Prognosis
- FLIPI — Follicular Lymphoma International Prognostic Index · Cancer Prognosis
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Morphine Slow-Release (Elderly Chronic Pain) · Opioid Analgesic — Modified-Release Oral
- Methyldopa (Chronic Hypertension in Pregnancy) · Centrally Acting Antihypertensive
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.